(Q43973073)

28 November 2017

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. (English)

1 reference

28 November 2017

0 references

Ahmad I

1

1 reference

28 November 2017

Islam T

2

1 reference

28 November 2017

Chanan-Khan A

3

1 reference

28 November 2017

Hahn T

4

1 reference

28 November 2017

Wentling D

5

1 reference

28 November 2017

Becker JL

6

1 reference

28 November 2017

McCarthy PL Jr

7

1 reference

28 November 2017

Alam AR

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Bone Marrow Transplantation

28 November 2017

1 reference

28 November 2017

29

1 reference

28 November 2017

577-580

1 reference

28 November 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703522

28 November 2017

0 references

cites work

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

High-dose cytosine arabinoside in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

Vincristine and oral etoposide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

7 January 2021

HyperCVAD for VAD-resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

7 January 2021

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

7 January 2021

Thalidomide on the comeback trail

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703522

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703522

1 reference

Dimensions Publication ID

28 November 2017

0 references

1 reference